Dyne Therapeutics (NASDAQ:DYN) Trading Up 7% – Time to Buy?

Dyne Therapeutics, Inc. (NASDAQ:DYN) shares traded up 7% during mid-day trading on Wednesday . The stock traded as high as $19.39 and last traded at $19.3330. 114,684 shares changed hands during mid-day trading, a decline of 94% from the average daily volume of 1,923,842 shares. The stock had previously closed at $18.07.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on DYN shares. Evercore set a $33.00 price target on shares of Dyne Therapeutics in a research report on Friday, May 15th. HC Wainwright reduced their price target on Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating for the company in a research report on Tuesday, March 3rd. Morgan Stanley decreased their price target on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research note on Monday, March 2nd. Chardan Capital reaffirmed a “buy” rating and set a $38.00 price target on shares of Dyne Therapeutics in a research report on Monday, March 9th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. Three equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $33.85.

Dyne Therapeutics Trading Up 3.1%

The company has a debt-to-equity ratio of 0.17, a current ratio of 19.92 and a quick ratio of 19.92. The business has a 50-day simple moving average of $18.30 and a two-hundred day simple moving average of $18.09. The stock has a market cap of $3.27 billion, a price-to-earnings ratio of -6.15 and a beta of 1.09.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.04. During the same period last year, the firm earned ($1.05) earnings per share. Equities analysts forecast that Dyne Therapeutics, Inc. will post -3 EPS for the current fiscal year.

Insider Activity

In other news, CFO Erick Lucera sold 1,448 shares of the company’s stock in a transaction that occurred on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $26,585.28. Following the transaction, the chief financial officer owned 123,925 shares of the company’s stock, valued at approximately $2,275,263. This represents a 1.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 83,219 shares of the stock in a transaction that occurred on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total value of $1,512,921.42. Following the transaction, the director owned 7,962 shares in the company, valued at approximately $144,749.16. This trade represents a 91.27% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders acquired 9,000 shares of company stock valued at $156,800 and sold 1,559,462 shares valued at $29,814,746. 9.46% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in DYN. Hilton Head Capital Partners LLC acquired a new stake in shares of Dyne Therapeutics during the 1st quarter worth $26,000. Strs Ohio acquired a new stake in Dyne Therapeutics during the fourth quarter worth about $51,000. Aster Capital Management DIFC Ltd bought a new position in Dyne Therapeutics in the 4th quarter valued at about $84,000. Steward Partners Investment Advisory LLC raised its position in shares of Dyne Therapeutics by 102.1% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 4,880 shares of the company’s stock valued at $95,000 after buying an additional 2,465 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Dyne Therapeutics by 26.2% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,940 shares of the company’s stock worth $136,000 after acquiring an additional 1,440 shares during the period. 96.68% of the stock is owned by institutional investors and hedge funds.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.